Trial Information
Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population
Inclusion Criteria:
- Patients undergoing colonoscopy as part of their clinical care or part of screening
program.
- Complete endoscopic examination (up to the caecum)
- Adequate colonic preparation
Exclusion Criteria:
- - Incomplete colonoscopic examination due to technical causes e.g. difficult
colonoscopy, patient intolerance (N.B. a neoplastic mass causing lumen stenosis will
not be excluded.)
- Poor colonic preparation obscuring adequate mucosal examination.
- Patients who have received any treatment for CRC and/or adenomas.
- Patients with known malignancy elsewhere (i.e. non-colorectal malignancy)
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects
Outcome Time Frame:
16 months
Safety Issue:
No
Principal Investigator
Hany M Shehab, MD, MRCP
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cairo University
Authority:
Egypt: Science and Technological Development Fund
Study ID:
CRCS001
NCT ID:
NCT01793207
Start Date:
December 2012
Completion Date:
March 2014
Related Keywords:
- Colorectal Neoplasms
- Adenoma
- Colorectal Tumors
- Adenoma
- Neoplasms
- Carcinoma
- Colorectal Neoplasms